"This webinar was such an informative session from both market standpoint and from medical device technical consideration standpoint."
9/10 Rating -Post event audience survey
Insights and data on how COVID-19 is changing medical device commercialization. Experts in medical device development, regulatory affairs and venture capital investment share experiences and learnings from ongoing commercialization projects.
View recording of 90-minute live webinar.
Virtual Medical Device Playbook is moderated by Scott Phillips, CEO and Founder of StarFish Medical and Founder of Medical Device Commercialization Playbook events in Toronto and Vancouver.
NEW COMMERCIALIZATION OPPORTUNITIES: Technological considerations to diagnostics development; What’s the point of ‘point of care’ diagnostics, Future proof and prepare for a wave of ‘COVID Complex Related Diseases’ opportunities
REGULATORY IMPACT: Emergency Use Authorizations (EUA) - Seeking regulatory clearance for Diagnostic Devices; Post-EAU Clearance requirements; When COVID-19 is no longer a pandemic, what can you do with your EAU devices?
INVESTMENT LANDSCAPE HOTSPOTS: Increased telemedicine and telehealth technologies and services; More point-of-care and home DIY diagnostic services; Accelerated development of new medical treatments and technologies with expanded access to care; Greater emphasis on R&D for targeted therapies and personalized healthcare
CEO and Founder - StarFish Medical
Scott is a Chair of the LifeSciences British Columbia board, Fellow of The Canadian Academy of Engineering, winner of the EY Entrepreneur Of The Year™ 2017 Pacific Awards Technology category, 2017 recipient of the VIATEC Technology Champion award, and volunteers with Junior Achievement, Entrepreneurs Organization, and University of British Columbia.
Manager, Bio Services - StarFish Medical
Nick Allan has over 19 years of regulatory and product development experience in the field of microbiology. His innovative solutions to client issues range from proof-of-concept studies for anti-infective candidates, to full scale regulatory submission studies. Nick was a key contributor to ASTM E2799-11 (the first protocol approved by ASTM that is both a biofilm growth and disinfectant protocol substantiated by a multi-laboratory collaborative study). Allan holds an MS in Microbiology and BS in Biology from the University of Guelph.
Senior QA/RA Consultant - Emergo by UL
Daryl Wisdahl is a Senior QA/RA Consultant for Emergo by UL based in Seattle. With more than 25 years of experience in the medical device industry Daryl assists with regulatory, quality, clinical and general business strategy development for medical device companies. He currently supports manufacturers in the US, Canada and internationally, and is the Program Manager for the Internal Auditor program at Emergo.
General Partner - New Ventures Funds
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.
He currently serves as General Partner at New Ventures Funds. Before joining New Ventures Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Venture